Compare FNWD & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | FATE |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.7M | 125.6M |
| IPO Year | 1996 | 2013 |
| Metric | FNWD | FATE |
|---|---|---|
| Price | $44.65 | $2.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $37.50 | $4.10 |
| AVG Volume (30 Days) | 20.6K | ★ 2.7M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ 0.52 | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $85.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.12 | $0.91 |
| 52 Week High | $45.00 | $3.23 |
| Indicator | FNWD | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 81.93 | 42.33 |
| Support Level | $35.02 | $1.01 |
| Resistance Level | N/A | $3.22 |
| Average True Range (ATR) | 0.76 | 0.21 |
| MACD | 0.74 | -0.09 |
| Stochastic Oscillator | 92.00 | 11.22 |
Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.